Role of Interleukin-35 Combined with Lymphocyte/Monocyte Ratio in Patients with Sepsis To investigate the value and role of serum interleukin-35 and lymphocyte/monocyte ratio for the prognostic assessment of sepsis cases is the main objective of the study. 78 sepsis patients sera was collected from October 2019 to October 2021 in our intensive care unit and were classified as survival (n=45) and death (n=33) groups based on their prognosis. In addition, 50 normal healthy subjects were also enrolled as control. Then, interleukin-35 contents in serum and lymphocyte/monocyte ratio of different groups were measured separately. We also analyzed the association of serum interleukin-35 with lymphocyte/ monocyte ratio among 78 sepsis cases and performed survival analysis on the serum interleukin-35 levels. Interleukin-35 expression of survival group increased relative to normal group, with no significant difference (p>0.05). Death group had markedly increased interleukin-35 expression compared with survival and normal groups (p<0.05) and difference in the lymphocyte/monocyte ratio values between death and survival groups was of no statistical significance (p>0.05). Interleukin-35 was not evidently correlated with lymphocyte/monocyte ratio (p>0.05). Survival analysis showed that sepsis cases with high interleukin-35 expression had significantly decreased survival, relative to low interleukin-35 expression (p<0.05). Serum interleukin-35 is the prognostic biomarker for sepsis cases and high interleukin-35 expression during early sepsis may indicate poor prognosis and the concentration of interleukin-35 levels has a high prognostic assessment value for sepsis survival compared with lymphocyte/monocyte ratio levels.